FOLFOX plus bevacizumab alternated with sLV5FU2 plus bevacizumab as first-line chemotherapy for patients with metastatic colorectal cancer: a feasibility study

Not Applicable

• Conditions: Colorectal cancer

• Registration Number: JPRN-UMIN000003673
• Lead Sponsor: niversity of Toyama

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2010-05-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

1. Brain metastasis 2. Massive pleural effusion or ascites 3. Active other malignancies 4. Nonhealing wound 5. Surgical procedure within 28 days before registration 6. Severe complications(bowel obstruction, symptomatic cardiovascular disease, interstitial pneumonitis, pulmonary fibrosis, uncontrollable hepertension, uncontrollable diabetes mellitus, active peptic ulcer, bleeding diathesis) 7. History of thromboembolitic disease 8. Uncontrollable diarrhea 9. Administration of corticosteroids 10. Administration of anticoagulants 11. Peripheral neuropathy 12. Active infectious disease 13. History of severe drug hypersensitivity 14. Psychosis 15. Pregnant or breast-feeding women 16. Men of wishing fertility 17. Not appropriate for the study at the physician's assessmnt

Study & Design

• Study Type: Interventional
• Study Design: Not specified